NextCure, Inc.
NXTCNASDAQHealthcareBiotechnology
Previous close
$6.29
+$0.04 · +0.64%
Pre-market
$6.29
$0.00 · 0.00%
Aug 24, 7:25 AM ET
NXTC company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
45
Fair Value
Momentum
20
Strong Down
Sentiment
45
Mixed
Risk resilience
25
High Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteNextCure, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative immunotherapies. Its core mission is to combat cancer and various other immune-related conditions by reactivating normal immune system function. The company's leading investigational compound, NC318, is currently in Phase II clinical trials, focusing on the treatment of advanced or metastatic solid tumors. Additionally, NextCure is progressing NC410 through Phase I studies; this novel immunomedicine is engineered to counteract immune suppression mediated by Leukocyte-Associated Immunoglobulin-like Receptor 1 (LAIR-1). Another asset, NC762, is an immunotherapeutic designed to target the human B7 homolog 4 protein (B7-H4). Furthermore, NC525, a distinct LAIR-1 antibody, is undergoing preclinical assessment for its potential efficacy against acute myeloid leukemia, specifically targeting blast cells and leukemic stem cells. Beyond these specific pipeline candidates, NextCure's broader research and development efforts encompass the preclinical evaluation of other promising immunomodulatory antibodies and molecules. The company operates under a licensing agreement with Yale University. NextCure, Inc. was established in 2015 and maintains its corporate headquarters in Beltsville, Maryland.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Michael S. Richman
- Listed since
- May 9, 2019
- Employees
- 40
Market position
Day range
Current $6.29
52-week range
Current $6.29
- Open
- $6.575
- Previous close
- $6.25
- Volume
- 36.97K
- 0.02× average
- Average volume
- 2.13M
- Average daily volume
- Market cap
- 22.72M USD
- Beta
- 1.27
- Market reference 1
- 50-day average
- $4.2451
- +48.17% above average
- 200-day average
- $9.232
- -31.87% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 19.51M USD
- P/E (TTM)
- -0.59×
- P/B (TTM)
- 2.75×
- P/S (TTM)
- 0×
- EV / EBITDA
- -0.36×
- Earnings yield
- -138.45%
- Free cash flow yield
- -123.00%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 0.00%
- Operating margin
- 0.00%
- Net margin
- 0.00%
- Return on equity
- -159.81%
- Return on assets
- -111.28%
- Return on invested capital
- -141.83%
Financial health
- Debt / equity
- 0.35×
- Current ratio
- 4.14×
- Altman Z-score
- -32.61
- Piotroski F-score
- 1 of 9
Financial statements
Income trends
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | 2.19M USD | — | — | — | — |
| Gross profit | −2.19M USD | — | — | — | — |
| Research and development | 44.92M USD | 41.49M USD | 47.93M USD | 54.2M USD | 50.19M USD |
| Selling, general, and administrative | 12.69M USD | 15.72M USD | 19.71M USD | 21.71M USD | 20.57M USD |
| Operating expenses | 55.43M USD | 59.75M USD | 67.64M USD | 75.91M USD | 70.77M USD |
| Interest income | — | — | — | 1.17M USD | 1.32K USD |
| Interest expense | — | — | — | — | 77K USD |
| Depreciation and amortization | 2.19M USD | 2.87M USD | 3.68M USD | 4.12M USD | 4.18M USD |
| Operating income | −57.62M USD | −59.75M USD | −67.64M USD | −75.91M USD | −70.77M USD |
| Net income | −55.84M USD | −55.65M USD | −62.72M USD | −74.73M USD | −69.39M USD |
Company facts updated Aug 24, 2026.
Earnings
- EPS beat rate
- 27%
- 3 beats, 8 misses, 0 met estimates
- Average EPS surprise
- -618.67%
- 11 comparable reports
- Latest EPS result
- -2.8
- Estimate -1.95 · Miss by 43.59%
EPS: actual versus estimate
Recent quarterly results
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Analyst price target
Average target
$20.00
217.97% upsideRating distribution
13 ratingsRecent analyst actions
NXTC news
Corporate actions
Corporate action history
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Jul 14, 2025 | 1:12 | — | — |
Effective Jul 14, 2025
1:12
NXTC peers
ETFs holding NXTC
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI510.98K0.00%2.3T USD0.03%$378.24+0.44%
Vanguard Extended Market ETFVXF139.13K0.00%93.7B USD0.05%$245.53+0.82%
iShares Micro-Cap ETFIWC62.38K0.00%1.53B USD0.60%$198.39+1.10%
Dimensional - US Core Equity 2 ETFDFAC371.110.00%49.31B USD0.17%$45.61+0.46%
U.S. Micro Cap Portfolio ETFDFMC137.50.00%8.06B USD0.43%$60.95+0.73%Vanguard Morningstar Total Stock Market ETFVTI- Market value
- 510.98K
- Weight
- 0.00%
- AUM
- 2.3T USD
- Expense ratio
- 0.03%
- Price / 1D
- $378.24+0.44%
Vanguard Extended Market ETFVXF- Market value
- 139.13K
- Weight
- 0.00%
- AUM
- 93.7B USD
- Expense ratio
- 0.05%
- Price / 1D
- $245.53+0.82%
iShares Micro-Cap ETFIWC- Market value
- 62.38K
- Weight
- 0.00%
- AUM
- 1.53B USD
- Expense ratio
- 0.60%
- Price / 1D
- $198.39+1.10%
Dimensional - US Core Equity 2 ETFDFAC- Market value
- 371.11
- Weight
- 0.00%
- AUM
- 49.31B USD
- Expense ratio
- 0.17%
- Price / 1D
- $45.61+0.46%
U.S. Micro Cap Portfolio ETFDFMC- Market value
- 137.5
- Weight
- 0.00%
- AUM
- 8.06B USD
- Expense ratio
- 0.43%
- Price / 1D
- $60.95+0.73%
Continue in GoAI
Research NXTCresearch.disclaimer